TherapeuticsMD Inc (NASDAQ:TXMD) has been given a consensus recommendation of “Hold” by the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $12.50.
A number of brokerages have recently weighed in on TXMD. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of TherapeuticsMD in a research note on Friday, November 23rd. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 5th. Oppenheimer set a $14.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, November 7th. Finally, ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Monday, October 29th.
Shares of NASDAQ TXMD opened at $5.15 on Friday. TherapeuticsMD has a twelve month low of $3.51 and a twelve month high of $7.66. The company has a market capitalization of $1.06 billion, a PE ratio of -13.92 and a beta of 1.54. The company has a current ratio of 7.23, a quick ratio of 7.15 and a debt-to-equity ratio of 0.55.
In other news, CFO Daniel A. Cartwright sold 40,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $4.85, for a total value of $194,000.00. Following the transaction, the chief financial officer now owns 40,000 shares of the company’s stock, valued at $194,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Robert G. Finizio sold 184,910 shares of the company’s stock in a transaction on Thursday, December 20th. The stock was sold at an average price of $3.66, for a total transaction of $676,770.60. Following the completion of the transaction, the chief executive officer now directly owns 18,458,559 shares in the company, valued at approximately $67,558,325.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,418,075 shares of company stock worth $16,259,415. Insiders own 22.85% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TXMD. FMR LLC increased its stake in TherapeuticsMD by 14.7% in the third quarter. FMR LLC now owns 12,049,988 shares of the company’s stock valued at $79,048,000 after acquiring an additional 1,542,987 shares during the last quarter. BlackRock Inc. increased its stake in TherapeuticsMD by 10.6% in the third quarter. BlackRock Inc. now owns 16,070,569 shares of the company’s stock valued at $105,421,000 after acquiring an additional 1,537,045 shares during the last quarter. Perceptive Advisors LLC bought a new position in TherapeuticsMD in the third quarter valued at $9,840,000. Nexthera Capital LP bought a new position in TherapeuticsMD in the third quarter valued at $8,575,000. Finally, Vanguard Group Inc increased its stake in TherapeuticsMD by 9.8% in the third quarter. Vanguard Group Inc now owns 12,894,027 shares of the company’s stock valued at $84,585,000 after acquiring an additional 1,153,716 shares during the last quarter. 72.64% of the stock is currently owned by institutional investors and hedge funds.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
See Also: The risks of owning bonds
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.